Key facts
- Beams (Therapeutic Devices)’s last known valuation is $10.8M (Oct 2025).
- It has raised $2.3M; the latest was Early Stage VC ($1.4M) in Oct 2025.
- Notable investors include Agoranov, 3DEXPERIENCE Lab, WA Proyectos Steam, WeLikeStartup.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Beams (Therapeutic Devices)
- ·The full record, as it builds
Funding rounds
No funding rounds for Beams (Therapeutic Devices) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Beams (Therapeutic Devices)
Developer of cancer monitoring technology designed to improve oncology therapy. The company's technology forms a combination of a beta particle detector and a surgical aspirator that is used for diagnosis and internal radiotherapy, enabling surgeons to make a precise distinction between healthy and tumorous tissues during surgery and ensure clear margins.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2021
- Employees
- 1
- Website
- beams.bio/
- Ownership
- Privately Held (backing)
Beams (Therapeutic Devices) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Beams (Therapeutic Devices) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Beams (Therapeutic Devices) in its N-PORT filings yet. We sweep new filings monthly.